KENUP-FOUNDATION
1.10.2020 10:10:11 CEST | Business Wire | Press release
On Wednesday, September 30, 2020, Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading Israeli regenerative medicine company developing a platform of novel biological products, and the Abu Dhabi Stem Cells Center (ADSCC) unveiled their first joint projects in a presentation at the Malta Conferences Foundation (MCF), a global conference supported by kENUP Foundation , a promoter of research-based innovation with public and societal benefit.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201001005476/en/
Pluristem and ADSCC presented new projects, part of the recently signed Memorandum of Understanding aimed at harnessing the power of regenerative medicine.
The first joint project brings together the expertise of Pluristem and ADSCC to advance a potential COVID-19 treatment. The project will involve the first-time administration of Pluristem’s PLX cells via a nebulizer, a drug delivery device that helps a patient inhale medication through a mask or mouthpiece, to COVID-19 patients. The collaboration allows ADSCC to expand their stem cell therapy options using Pluristem’s PLX cells, while enabling Pluristem to leverage ADSCC’s nebulizer administration experience to develop a new treatment delivery model for PLX cells. ADSCC has reported effectively using nebulizers to treat COVID-19 patients with stem cells sourced from the patient’s own blood.
Further discussions for additional projects are underway, including for potential collaboration in chronic Graft Versus Host Disease (cGvHD), a life-threatening immune response of the donor’s stem cells against the host (patient).
The parties presented the joint projects to a distinguished audience at the MCF, including Nobel Laureates, scientists, and diplomats. The foundation’s mission is to address the shared desire to improve quality of life and political stability in the Middle East by identifying opportunities for collaboration to meet the scientific and technological challenges of the region.
“I am delighted for the opportunity to convene this important meeting. The Malta Conferences are the only platform in the world where scientists from 15 Middle East countries, Morocco and Pakistan can get together under the same roof with several Nobel Laureates. They develop collaborations and friendship which overcome the chasms of distrust and intolerance.” said Prof. Zafra Lerman, President of Malta Conferences Foundation.
“Embarking on this journey with Pluristem to overcome one of this generation’s most complex medical challenges marks an exciting new chapter full of possibilities when it comes to knowledge sharing and medical innovation. Our partnership speaks volumes about the power of collaboration between partners across previously divided borders. While we simply do not yet know the long-term impact the novel coronavirus will have on recovered patients, by working together we believe we are able to leverage the best medical technologies and minds in the region to develop solutions to prevent and treat the lingering symptoms and long-term complications that are emerging.” said Dr. Yendry Ventura, General Manager of ADSCC.
“We were very honored to unveil our first joint projects with the ADSCC at the MCF. We see our partnership as a movement between Israel and the UAE, which we hope will lay the foundation for future collaborations that will help potentially bring change to our region and the world. As we work together to develop regenerative medicine for key unmet medical needs of benefit to patients around the world, we are excited for the future and its possibilities,” stated Pluristem CEO and President Yaky Yanay.
‘Two world-class players in cell therapy join forces and cooperate on the fight of COVID-19. May this courageous cooperation serve as an example to the world’, says kENUP Foundation’s Executive Chairman Holm Keller.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201001005476/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Randomized Controlled Trial Shows Promise of a Ketogenic Diet in Psychotic Disorders8.7.2026 15:00:00 CEST | Press release
Trial reports correlations between ketone levels and cognitive and psychiatric symptoms in individuals with schizophrenia-spectrum and bipolar-1 disorders Published today in Schizophrenia Bulletin, a first-of-its-kind randomized controlled trial (RCT) from researchers at the University of California, San Francisco (UCSF), and funded in part by the National Institute of Mental Health (NIMH), adds to growing literature on the potential benefit of a ketogenic diet for treating psychotic disorders. The study, which enrolled participants with schizophrenia-spectrum or bipolar-1 disorders, demonstrated rapid metabolic improvements with a ketogenic diet compared to diet-as-usual during an initial one-month RCT open-label phase. Furthermore, those who continued with the optional four-month single-arm ketogenic diet extension saw meaningful gains across metabolic, psychiatric, and cognitive measures. This press release features multimedia. View the full release here: https://www.businesswire.co
Teamily AI Publicly Launches Human+AI Social Platform to Make Building and Growing a Company Easy for Every Team8.7.2026 15:00:00 CEST | Press release
Teamily AI (https://Teamily.ai), together with its Agentic AI Infra platform TensorOpera AI (https://TensorOpera.ai), today announced the public launch of its Human+AI social platform, a product stack that has already served more than 5 million users around the world. Starting today in Palo Alto and rolling out simultaneously across dozens of countries, this first public launch opens the full stack to everyone with a single mission: to make building and growing a company easy for every person and every team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708584390/en/ "This is the moment we open our doors to the world," said co-founders Dr. Aiden Chaoyang He and Professor Salman Avestimehr. "We want every person and every team to be able to move from idea to product, from product to market, and from market to growth and investment, with an AI-native team by their side." At its core, Teamily AI enables humans and AI agents
Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform8.7.2026 14:30:00 CEST | Press release
Oversubscribed round follows the world-first compact upright proton treatment at Stanford Medicine — funding a single upright platform that will span imaging and treatment across multiple radiation modalities. Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. Leading cancer institutions are already adopting the upright approach. Stanford Medicine delivered the world’s first compact upright proton therapy treatment on 4 June 2026. Dana-Farber Cancer Institute and McLaren Health Care are among the institutions bringing the upright platform into their programmes — adoption that spans world-leading academic centers and
LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development8.7.2026 14:00:00 CEST | Press release
The Halocene H4 quantum computer, named LUMI-IQ, will be delivered and installed in 2027 The system will be hosted at CSC – IT Center for Science in Finland and integrated into the LUMI AI Factory The system will provide researchers, industry innovators, and developers across Europe with a unique, advanced experimental platform where quantum computing and artificial intelligence converge The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/ LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer o
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations8.7.2026 14:00:00 CEST | Press release
Enpatoran could address a significant unmet need in lupus, specifically targeting cutaneous manifestations of the disease, which currently have no approved therapiesFDA's decision was supported by Phase 2 WILLOW study results, which demonstrated meaningful symptoms improvement, particularly among patients with active cutaneous manifestationsEnpatoran's potential to go beyond current treatment standards in lupus prompted FDA´s breakthrough designation, which is designed to expedite drug development and reviewNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manif
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom